Ranibizumab
Discovery
Development
Clinical
Filed
Commercialized
Therapeutic area
Therapeutic area
Ophthalmology
Reference product
Reference product
Lucentis® (Novartis)
Commercial partners
Commercial partners
Teva, MS Pharma
Status
Status
Commercialised through Bioeq AG, a joint venture between Polpharma Biologics and Formycon AG
In-market brands
About this program
Ranibizumab is a biosimilar developed to match Lucentis®, a reference biologic used in the treatment of neovascular age-related macular degeneration and other retinal conditions.
Commercialization partners
Sandoz
EU
US
Germany
Zydus Lifesciences
US
EU
UK
Canada
Let's build together.
If you want to explore what a partnership with us could look like, we're ready to talk.